Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, Morgan RC, Mellon K, Morash C, Parulekar W, Parmar MKB, Payne H, Savage C, Stansfeld J, The RADICALS Trial Management Group.
Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU International. 2007; 99:1376-1379
Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S.
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology. 2007; 139:70-80
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens R.J., Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T.
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology. 2008; 26:3552-3559
Parker CC, Clarke NP, Kynaston H, Sydes MR.
When should radiotherapy be used after radical prostatectomy? The RADICALS-RT Trial. British Journal of Medical and Surgical Urology. 2010; 3:190-193
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du BA, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM.
A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine. 2011; 365:2484-2496
Paediatric European Network for Treatment of AIDS (PENTA).
Highly active antiretroviral therapy started in infants under 3 months of age: 72 week follow-up for CD4 cell count, viral load and drug resistance outcomes. AIDS. 2004; 18:237-245
Phillips AN, Walker AS.
Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS. 2004; 18:365-370
Pace C, Emanuel EJ, Chuenyam T, Duncombe C, Bebchuk JD, Wendler D, Tavel JA, McNay LA, Phanuphak P, Forster HP, Grady C, for the ESPRIT Group.
The quality of informed consent in a clinical research study in Thailand. IRB: Ethics Human Research. 2005; 27:9-17
Paton NI, Aboulhab J.
Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Medicine. 2005; 6:13-20
Pickering J, Whitworth JAG, Hughes P, Kasse M, Morgan D, Mayanja B, Van der Paal L, Mayaud P.
Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. Sexually Transmitted Infections. 2005; 81:488-493